Tubular Endogenous Erythropoietin Protects Renal Function against Ischemic Reperfusion Injury
Authors:
- Yukiko YasuokaYYYukiko Yasuoka
- Yuichiro IzumiYIYuichiro Izumi
- Takashi FukuyamaTFTakashi Fukuyama
- Tomomi OshimaTOTomomi Oshima
- Taiga YamazakiTYTaiga Yamazaki
- Takayuki UematsuTUTakayuki Uematsu
- Noritada KobayashiNKNoritada Kobayashi
- Masayoshi NanamiMNMasayoshi Nanami
- Yoshitaka ShimadaYSYoshitaka Shimada
- Yasushi NagabaYNYasushi Nagaba
- Masashi MukoyamaMMMasashi Mukoyama
- Jeff M SandsJSJeff M Sands
Preprint
- 27 November 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Many large-scale studies revealed that exogenous erythropoietin, erythropoie-sis-stimulating agents, have no renoprotective effects. We investigated the effects of en-dogenous erythropoietin on renal function in ischemic reperfusion injury (IRI) of kidney using prolyl hydroxylase domaine (PHD) inhibitor, Roxadustat (ROX). 4 hr hypoxia (7% O2) and 4 hr treatment by ROX prior to IRI did not improve renal function. In contrast, 24-72 hr pre-treatment by ROX largely improved the decline of renal function by IRI. Hy-poxia and 4 hr ROX increased interstitial cells-derived Epo production by 75 and 6-fold, respectively, before IRI and worked as exogenous Epo. 24-72 hr ROX treatment increased Epo production during IRI by 9-fold. Immunohistochemistry revealed that 24 hr ROX caused Epo production in proximal and distal tubules and worked as endogenous Epo. Our data show that 24-72 hr ROX-induced tubular endogenous Epo production results in renoprotection but peritubular exogenous Epo production by interstitial cells-derived in-duced by hypoxia and 4 hr ROX did not. Stimulation of tubular but not peritubular Epo production may link to renoprotection.Keywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Neurogenic and pericytic plasticity of conditionally immortalized cells derived from renal erythropoietin‐producing cellsJournal of Cellular Physiology, 2022
- Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantagesEuropean Journal of Pharmacology, 2021
- Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stressDrug Development Research, 2021
- Differentiation of endogenous erythropoietin and exogenous ESAs by Western blottingHeliyon, 2020
- Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialAdvances in Therapy, 2019
- Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ductsBiochemical and Biophysical Research Communications, 2018
- Erythropoietin Regulation by Angiotensin II2017
- Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasisPflügers Archiv - European Journal of Physiology, 2015
- Reevaluation of erythropoietin production by the nephronBiochemical and Biophysical Research Communications, 2014
- Regulation of erythropoiesis by hypoxia-inducible factorsBlood Reviews, 2013